secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001100682-24-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q3 revenue $1.01B (-1.6% YoY); non-GAAP EPS $2.59 beats prior outlook; narrows FY guidance
--------------------------------------------------------------------------------

- Revenue $1.01B, down 1.6% YoY (organic -2.7%); GAAP EPS $1.33, non-GAAP EPS $2.59.
- DSA segment organic revenue fell 7.4%; Manufacturing organic revenue grew 11.8%.
- Board approved $1B stock repurchase; $100.7M spent in Q3, $899.3M remaining.
- FY 2024 guidance narrowed: reported revenue (3%)-(2%); non-GAAP EPS raised to $10.10-$10.30.
- CEO cites stable demand indicators and biotech funding improvement; restructuring actions continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068224000033/0001100682-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068224000033/crl-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001100682-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer